The Claim
The number needed to treat (NNT) to prevent one major adverse cardiovascular event over three years with GLP-1 receptor agonists is 47 in type 2 diabetes patients with pre-existing atherosclerotic cardiovascular disease and 109 in those without pre-existing atherosclerotic cardiovascular disease.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Among type 2 diabetes patients, GLP-1 receptor agonists prevent one major cardiovascular event in every 47 patients with existing heart disease over three years, and in every 109 patients without existing heart disease.
See the scientific wording
The number needed to treat (NNT) to prevent one major adverse cardiovascular event over three years with GLP-1 receptor agonists is 47 in type 2 diabetes patients with pre-existing atherosclerotic cardiovascular disease and 109 in those without, indicating substantially greater clinical efficiency in higher-risk populations.
GLP-1 receptor agonists slow the buildup of fatty plaques in arteries and make existing plaques less likely to rupture, which prevents heart attacks and strokes.
What the research says
1 studyThe study shows that for diabetic patients who already have heart disease, you need to treat only 47 people with the drug to prevent one serious heart event in three years — but for those without heart disease, you need to treat 109 people. So the drug works better in people already at higher risk.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.